Evidence map›Paper›PMID 41331195›Full record

ArticleJournal of computer-aided molecular design2025

DeepTargetClass: a web-based platform for predicting protein target classes of small molecules.

Mebarka Ouassaf, Bader Y Alhatlani

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mebarka OuassafLMCE Laboratory, Group of Computational and Medicinal Chemistry, University of Biskra, 07000, Biskra, Algeria. nouassaf@univ-biskra.dz.
Bader Y AlhatlaniUnit of Scientific Research, Applied College, Qassim University, 52571, Buraydah, Saudi Arabia. balhatlani@qu.edu.sa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of protein target classes is a key step in drug discovery, as it enables prioritization of screening campaigns and supports target-based drug repurpose. In this study, we developed a deep-learning pipeline based on a multilayer perceptron (MLP) trained on 15,804 curated compounds representing four major pharmacological target classes: G protein-coupled receptors (GPCRs), kinases, nuclear receptors, and transporters. Using extended connectivity fingerprints (ECFP4) as molecular descriptors, the model achieved 96% accuracy in internal cross-validation and 87% accuracy on an external test set, demonstrating performance comparable to ensemble classifiers such as Random Forest, XGBoost, and LightGBM. Class-specific F1 scores confirmed robust and balanced predictions across GPCR, kinase, nuclear receptor, and transporter categories. Model interpretability was addressed using SHAP values, which highlighted pharmacophore-like substructures consistent with known ligand-target interactions. Application to reference drugs further validated predictive utility, with correct assignment of most compounds to their canonical protein target class. The final MLP model was deployed as a user-friendly web application to facilitate accessible protein class prediction for novel compounds. Overall, this work presents a reliable and interpretable computational framework to support target-class-based drug discovery and repositioning.

Indexed as

Deep LearningDrug DiscoveryProteinsSmall Molecule LibrariesHumansInternetLigandsReceptors, Cytoplasmic and NuclearReceptors, G-Protein-CoupledLigandsProteinsReceptors, Cytoplasmic and NuclearReceptors, G-Protein-CoupledSmall Molecule LibrariesDeep learningDrug discoveryECFP4 fingerprintsInterpretable AIProtein target classSHAP

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.